Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 305

The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

Open access
Pol, Jonathan, Vacchelli, Erika, Aranda, Fernando, Castoldi, Francesca, Eggermont, Alexander, Cremer, Isabelle, Sautès-Fridman, Catherine, Fucikova, Jitka, Galon, Jérôme, Spisek, Radek, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo·2015·OncoImmunology

Abstract

The term “immunogenic cell death” (ICD) is now employed to indicate a functionally peculiar form of apoptosis that is sufficient for immunocompetent hosts to mount an adaptive immune response against dead cell-associated antigens. Several drugs have been ascribed with the ability to provoke ICD when employed as standalone therapeutic interventions. These include various chemotherapeutics routinely employed in the clinic (e.g., doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin) as well as some anticancer agents that are still under preclinical or clinical development (e.g., some microtubular inhibitors of the epothilone family). In addition, a few drugs are able to convert otherwise non-immunogenic instances of cell death into bona fide ICD, and may therefore be employed as chemotherapeutic adjuvants within combinatorial regimens. This is the case of cardiac glycosides, like digoxin and digitoxin, and zoledronic acid. Here, we discuss recent developments on anticancer chemotherapy based on ICD inducers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2015.1008866

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 159 references

Research works printed but not linked: 17

  1. Ibrahim A, 2003, Clin Cancer Res, 9, 2394
  2. Roulstone V, 2015, Clin Cancer Res
  3. Marks E, 2014, JOP, 15, 99
  4. 10.1517/13543780903530678 · doi:10.1517/13543780903530678
  5. 10.1245/s10434-014-3844-x · doi:10.1245/s10434-014-3844-x
  6. Delfino C, 2012, G Ital Dermatol Venereol, 147, 573
  7. 10.1111/j.1600-0625.2009.00993.x · doi:10.1111/j.1600-0625.2009.00993.x
  8. 10.1111/j.1600-0625.2009.00995.x · doi:10.1111/j.1600-0625.2009.00995.x
  9. 10.1093/annonc/mdt480 · doi:10.1093/annonc/mdt480
  10. 10.1158/2159-8290.CD-RW2014-112 · doi:10.1158/2159-8290.cd-rw2014-112
  11. 10.1126/science.8091216 · doi:10.1126/science.8091216
  12. 10.4161/onci.26098 · doi:10.4161/onci.26098
  13. 10.1007/s00280-012-2044-2 · doi:10.1007/s00280-012-2044-2
  14. 10.4161/onci.27622 · doi:10.4161/onci.27622
  15. 10.1186/1756-9966-32-49 · doi:10.1186/1756-9966-32-49
  16. 10.1007/s00280-014-2523-8 · doi:10.1007/s00280-014-2523-8
  17. 10.1093/annonc/mdu485 · doi:10.1093/annonc/mdu485

Cited by

See all 305

Metadata

Authors
Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L.
Venue
OncoImmunology
Published
2015-03-02
Volume
4
Issue
4
Pages
e1008866
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W1779771004
Cited by
305
References
159
FWCI
12.23
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. https://app.cochat.ai/papers/10.1080/2162402x.2015.1008866
The paper
Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. OncoImmunology. https://doi.org/10.1080/2162402x.2015.1008866

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.